Leading US centre for cancer research implements high content screening technology to enhance its development of novel assays to be used in its cancer research programmes
Cellomics has announced a collaborative agreement with the University of California, San Francisco (UCSF) Comprehensive Cancer Centre.
UCSF will implement Cellomics's high content screening (HCS) technology to enable the Cancer Centre to further advance its cancer biology research capabilities.
One of the world's leading academic cancer research institutions, the UCSF Comprehensive Cancer Centre will use Cellomics ArrayScan HCS reader, KineticScan HCS reader, vHCS discovery toolbox and Cellomics's proprietary applications in their extensive research.
"We are extremely pleased the Comprehensive Cancer Centre has chosen to implement Cellomics's HCS technologies in itsr cancer biology research," stated Lansing Taylor, CEO of Cellomics.
"We are excited to be working with Dr Joe Gray, one of the world's leading cancer scientists with great expertise in cytometry.
In addition, we are confident the resulting data will enable the Cancer Centre to enhance its development of novel assays to be used in its cancer research programmes." Cellomics is pioneering the field of cellular knowledge extraction.
Its unique technology, referred to as high content screening, integrates fluorescent reagents, kits, cell lines, multi-parametric assays, HCS instrumentation (both fixed end-point and kinetics systems), and informatics tools to achieve a flexible, broadly applicable platform for users in the life sciences.
This automated platform, when applied to lead optimisation, predictive toxicology, and new target validation, is proving to reduce the 'idea-to-discovery' cycle time in drug discovery while increasing the probability of the therapeutic success of leads as well as reducing the cycle time in research and similar institutions.
Currently, Cellomics's proprietary ArrayScan and KineticScan HCS readers, along with its vHCS discovery toolbox software and proprietary applications, are in use at multiple sites within the top 15 pharmaceutical companies in the world, as well as several additional leading pharmaceutical and biotechnology companies, and academic centres. Housed within one of the top US biomedical research universities, the UCSF Comprehensive Cancer Centre brings together hundreds of researchers and clinicians dedicated to four fundamental pursuits: basic science research into the causes and events of cancer progression; clinical research to translate new knowledge into viable treatments; sensitive, state-of-the-art patient care; and programmes in epidemiology, prevention, and cancer control. Basic scientists and clinical health care providers work together toward the translation of promising ideas into the creation of new and better treatments for cancer patients everywhere.
